Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Quizartinib Plus Chemo Significantly Improves OS Vs Chemo Alone in Newly Diagnosed FLT3-ITD+ AML

June 11th 2022

The addition of quizartinib to standard induction and consolidation chemotherapy and then continued as a single agent doubled median overall survival vs standard chemotherapy alone in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

June 10th 2022

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Dr. Cordoba on the Efficacy of Epcoritamab in DLBCL

June 10th 2022

Raul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

PRO Results Show Zanubrutinib Improves HRQOL Vs Ibrutinib in R/R CLL/SLL

June 10th 2022

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.

Epcoritamab Plus GemOX Exhibits Promising Early Efficacy in R/R DLCBL

June 10th 2022

Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.

Epcoritamab Plus R-DHAX/C Demonstrates High Response Rates and Manageable Safety in DLBCL

June 10th 2022

Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.

Pirtobrutinib Under Exploration in Patients with Previously Treated MCL

June 10th 2022

Single-agent pirtobrutinib is being investigated for safety and efficacy in heavily pretreated, BTK inhibitor–naïve patients with mantle cell lymphoma in the ongoing phase 3 BRUIN-MCL-321 trial.

NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML

June 10th 2022

Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.

Updated CAPTIVATE Data Underscore Long-Term Benefits of Fixed-Duration Ibrutinib/Venetoclax in CLL/SLL

June 10th 2022

The fixed-duration, frontline combination comprised of ibrutinib and venetoclax continued to produce deep, durable responses with a clinically meaningful progression-free survival benefit in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

June 10th 2022

Jorge J. Castillo, MD, discusses the phase 2 CLOVER WaM trial in Waldenström macroglobulinemia.

Zanubrutinib Continues to Provide Clinically Meaningful Advantages Over Ibrutinib in Waldenström Macroglobulinemia

June 9th 2022

Zanubrutinib continued to demonstrate a higher complete response or very good partial response rate and less off-target activity compared with ibrutinib in patients with MYD88-mutated Waldenström macroglobulinemia.

Role of MRD in Treatment Decision Making in AML

June 9th 2022

Two experts discuss the clinical implications of minimal residual disease (MRD) and how it has affected treatment for patients with acute myeloid leukemia (AML).

Considerations for Venetoclax + Azacitidine Administration and AE Management

June 9th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

Mosunetuzumab Approved in Europe for Relapsed/Refractory Follicular Lymphoma

June 8th 2022

The European Commission has granted a conditional marketing authorization for mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 systemic therapies.

Bristol Myers Squibb Withdraws sBLA for Luspatercept-aamt in Non–Transfusion Dependent Beta Thalassemia

June 8th 2022

The global biopharmaceutical company Bristol Myers Squibb has announced the withdrawal of a supplemental biologics license application that was seeking the approval of luspatercept-aamt for the treatment of anemia in adults with non–transfusion dependent beta-thalassemia.

Asciminib Represents New Standard of Care for Patients With CML in Chronic Phase

June 7th 2022

Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.

Key Subgroup Analyses Supports Tafasitamab Plus Lenalidomide for High-Risk R/R DLBCL

June 6th 2022

Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.

Liso-cel Elicits Significant Second-line Activity in Frail Patients with Relapsed/Refractory LBCL

June 5th 2022

Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.

RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma

June 5th 2022

The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Epcoritamab Plus R2 Elicits High Metabolic Response Rate in Relapsed/Refractory Follicular Lymphoma

June 4th 2022

The addition of subcutaneous epcoritamab to treatment with rituximab and lenalidomide resulted in a 100% response rate and a low incidence of low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, according to findings from arm 2 of the EPCORE NHL-2 trial.